Memantine + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Parkinson's Disease Dementia

Conditions

Parkinson's Disease Dementia, Dementia With Lewy Bodies

Trial Timeline

Jan 1, 2007 → Jan 1, 2009

NCT ID

NCT00855686

About Memantine + Placebo

Memantine + Placebo is a approved stage product being developed by Lundbeck for Parkinson's Disease Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00855686. Target conditions include Parkinson's Disease Dementia, Dementia With Lewy Bodies.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease Dementia were approved

Approved (20) Terminated (4) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04789915	Phase 1	Recruiting	May 26, 2021	Dec 31, 2026	Psychosis
NCT00638833	Phase 2	Terminated	Sep 1, 2007	Mar 1, 2008	Multiple Sclerosis
NCT00855686	Approved	Completed	Jan 1, 2007	Jan 1, 2009	Parkinson's Disease Dementia
NCT01074619	Phase 3	Completed	Sep 1, 2005	Nov 1, 2011	Multiple Sclerosis
NCT00862940	Approved	Completed	Sep 1, 2005	Apr 1, 2009	Alzheimer's Disease
NCT00857649	Phase 3	Terminated	Dec 1, 2003	Sep 1, 2010	Alzheimer's Disease

Competing Products

20 competing products in Parkinson's Disease Dementia

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40